110 related articles for article (PubMed ID: 32442786)
1. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
George G; Rezazadeh A; Zook F; Pearl N; McCoy C; Carlson K; Runaas L; Abedin S; Guru Murthy GS; Michaelis LC; Atallah E; Baumann-Kreuziger L
Leuk Res; 2020 Jul; 94():106368. PubMed ID: 32442786
[No Abstract] [Full Text] [Related]
2. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Chen J; Ngo D; Aldoss I; Shayani S; Tsai NC; Pullarkat V
Leuk Lymphoma; 2019 May; 60(5):1187-1192. PubMed ID: 30322332
[TBL] [Abstract][Full Text] [Related]
3. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
[TBL] [Abstract][Full Text] [Related]
4. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
Chen Y; Buhlinger K; Perissinotti AJ; Schepers AJ; Benitez L; Auten J; Chen SL; Bixby DL; Burke PW; Pettit KM; Marini BL
Leuk Lymphoma; 2022 Nov; 63(11):2663-2670. PubMed ID: 35699966
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Pinheiro JP; Lanvers C; Würthwein G; Boos J
Blood; 2002 Sep; 100(5):1923-4; author reply 1924-5. PubMed ID: 12211194
[No Abstract] [Full Text] [Related]
6. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Farrell K; Fyfe A; Allan J; Tait RC; Leach M
Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
[TBL] [Abstract][Full Text] [Related]
7. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole-induced hepatotoxicity following the administration of PEG-asparaginase: Case report.
Gallant R; Bonney P; Peek L; Yu Z; Crawford D
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27748018
[No Abstract] [Full Text] [Related]
9. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
[TBL] [Abstract][Full Text] [Related]
10. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
Cooperation Group of Phase II Clinical Trial of PEG-Asp
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
[TBL] [Abstract][Full Text] [Related]
12. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
13. Still trying to pick the best asparaginase preparation.
Rizzari C
Lancet Oncol; 2015 Dec; 16(16):1580-1. PubMed ID: 26549585
[No Abstract] [Full Text] [Related]
14. Shedding light on the asparaginase galaxy.
Rizzari C
Blood; 2014 Mar; 123(13):1976-8. PubMed ID: 24677398
[TBL] [Abstract][Full Text] [Related]
15. Cryoprecipitate-induced mesenteric venous thrombosis during L-asparaginase therapy for acute lymphoblastic leukaemia.
Musa MO; Al-Fair F; Al-Mohareb F; Al-Saeed H; Aljurf M
Leuk Lymphoma; 2001 Jan; 40(3-4):429-31. PubMed ID: 11426567
[TBL] [Abstract][Full Text] [Related]
16. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH.
Zwicker JI; Wang TF; DeAngelo DJ; Lauw MN; Connors JM; Falanga A; McMasters M; Carrier M
J Thromb Haemost; 2020 Feb; 18(2):278-284. PubMed ID: 31999063
[TBL] [Abstract][Full Text] [Related]
17. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
[TBL] [Abstract][Full Text] [Related]
18. Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia.
Zuurbier SM; Lauw MN; Coutinho JM; Majoie CB; van der Holt B; Cornelissen JJ; Middeldorp S; Biemond BJ; Stam J
J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1679-84. PubMed ID: 25934140
[TBL] [Abstract][Full Text] [Related]
19. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
20. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
